Call Us: 1.800.873.5297


Schlichter, Bogard & Denton’s Role in Yaz/Yasmin Litigation

Are you considering a lawsuit against Bayer Pharmaceuticals and Bayer Schering AG for injuries you suffered as a result of using Yaz or Yasmin birth control pills? Are you looking for the help of a law firm whose leadership on this type of litigation is recognized nationwide? Are you looking for lawyers that judges and other lawyers consider experts in pharmaceutical litigation?

If you are, then you are looking for Schlichter, Bogard & Denton. To learn more about our nationwide recognition and leadership in pharmaceutical litigation and how we can help you in your case, please contact us today for a free initial consultation.

Yaz and Yasmin Lawsuit Background

Bayer Pharmaceuticals, Inc. and Bayer Schering AG, the manufactures of theYaz/Yasmin, are facing hundreds of lawsuits as a result of injuries associated with their birth control products. The Judicial Panel of Multidistrict Litigation (JPML) has consolidated and transferred all Yaz/Yasmin federal actions to the Southern District of Illinois, assigned to Chief Judge David R. Hendon, thereby creating the In Re Yaz/Yasmin (Drospirenone) Marketing, Sales Practice and Products Liability Litigation MDL,  09-md-2100. Unlike a class action lawsuit, there is not a single trial that resolves all of the cases. Instead, the MDL case is consolidated under one federal judge who handles all of the discovery matters that are common to all of the defendants. See our page on class action vs. multidistrict litigation for more background information.

Schlichter, Bogard & Denton’s Role

As soon as the MDL was transferred to his court, Judge Herndon appointed the Steering Committee which includes Schlichter, Bogard & Denton partner Roger Denton as the liaison counsel. As liaison counsel, Roger Denton is charged with the responsibility of coordinating the document discovery, communicating with the Plaintiffs’ counsel of record and participating in the regular status conferences. Roger Denton, and the other Plaintiffs’ Steering Committee members, acts as the spokesperson for all plaintiffs during the pre-trial proceedings.

In an effort to control the litigation, the Plaintiffs’ Steering Committee has created the Discovery, Science and Expert, and Law and Briefing Committees. Among other things, the Discovery Committee has the task of reviewing millions of pages of documents produced by the Defendants. Schlichter, Bogard & Denton attorneys Kristine Kraft and Megan Vanderbeek are members of the Discovery Committee.

The Science and Expert Committee is busy reviewing literature and understanding the pharmacokinetics (the studies of what the body does to a drug) of Yaz/Yasmin and Ocella—the generic form of Yasmin. This committee will work closely with medical experts. Schlichter, Bogard & Denton attorneys Kristine Kraft and Beth Wilkins are members of the Science and Expert Committee. The Law and Briefing Committee, with attorneys Beth Wilkins and Kristie Blunt, researches and writes all of the legal arguments for the litigation.

If you have suffered a Yaz/Yasmin-related injury and are interested in working with a nationally-recognized leader in this litigation, please call or email Schlichter, Bogard & Denton today for a free initial consultation.

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.